The Role of Early Treatment in the Management of Axial Spondyloarthritis: Challenges and Opportunities
AbstractAxial spondyloarthritis (axSpA) is a chronic, inflammatory rheumatic disease that primarily affects the axial skeleton, often inflicting severe pain, diminished mobility, and a compromised quality of life. The advent of Assessment of SpondyloArthritis international Society (ASAS) classification criteria for spondyloarthritis (SpA) have enabled the classification of patients with axSpA in the non-radiographic stage but poorly perform if mistakenly used for diagnostic purposes. Despite notable progress in early diagnosis facilitated by referral strategies and extensive magnetic resonance imaging (MRI) utilization, di...
Source: Rheumatology and Therapy - December 18, 2023 Category: Rheumatology Source Type: research
Adalimumab Effectively Decreases Inflammation Downstream of TNF α Signaling in Synoviocytes from Extended Oligoarticular Juvenile Idiopathic Arthritis
ConclusionsThis data suggests that, after only 24 h, adalimumab is effective at decreasing inflammation that occurs downstream of initial TNFα signaling in extended-to-be fibroblast-like synoviocytes. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - December 9, 2023 Category: Rheumatology Source Type: research
Filgotinib Demonstrates Efficacy in Rheumatoid Arthritis Independent of Smoking Status: Post Hoc Analysis of Phase 3 Trials and Claims-Based Analysis
ConclusionsGreater proportions of MTX-IR current/former smokers responded to FIL200 + MTX vs. adalimumab + MTX. In non-smoking MTX-IR, bDMARD-IR, and MTX-naïve patients with RA, FIL200 + MTX demonstrated increased response vs. controls. Current/former smokers were likelier to discontinue adalimumab vs. non-smokers in real-world clinical settings.Trial RegistrationNCT02889796, NCT02873936, NCT02886728. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - December 6, 2023 Category: Rheumatology Source Type: research
Correction: Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis
(Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - December 2, 2023 Category: Rheumatology Source Type: research
Correction: Real-World Sarilumab Use and Rule Testing to Predict Treatment Response in Patients with Rheumatoid Arthritis: Findings from the RISE Registry
(Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - November 13, 2023 Category: Rheumatology Source Type: research
Decision Impact Analysis to Measure the Influence of Molecular Signature Response Classifier Testing on Treatment Selection in Rheumatoid Arthritis
ConclusionThis study showed that rheumatologists reported using the MSRC test to guide b/tsDMARD selection for patients with RA. In most cases, MSRC test results appeared to influence clinical decision-making according to physician self-report. Wider adoption of precision medicine tools like the MSRC could support rheumatologists and patients in working together to achieve optimal outcomes for RA. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - November 10, 2023 Category: Rheumatology Source Type: research
Epidemiology of Sj ögren’s: A Systematic Literature Review
ConclusionsThis SLR identified a paucity of incidence and prevalence data for primary Sj ögren’s, highlighting a need for further epidemiological studies. The global Sjögren’s community must work together to follow the defined classification criteria of primary Sjögren’s and reporting guidelines for incidence and prevalence data to allow for meaningful epidemiological compariso ns across studies, settings, and countries. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - November 10, 2023 Category: Rheumatology Source Type: research
Endovascular Interventional Procedure is a Significant Risk Factor of Postsurgical Gout: A Retrospective Cohort Study
ConclusionsPatients with a history of gout should be more alert to recurrence gout flares after endovascular interventional procedures. Adequate presurgical control of serum uric acid levels and/or prophylactic treatment with colchicine will help prevent gout flares during the postsurgical period. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - November 6, 2023 Category: Rheumatology Source Type: research
Tofacitinib Efficacy in Patients with Rheumatoid Arthritis and Probable Depression/Anxiety: Post Hoc Analysis of Phase 3 and 3b/4 Randomized Controlled Trials
ConclusionsThe percentage of patients with pMDD/pGAD reduced from baseline over 1 year of treatment with tofacitinib or adalimumab. Effective treatment of underlying RA may lead to improvements in depression and anxiety, based on the SF-36 MCS. Specially designed studies using gold-standard diagnostic tools would be warranted to investigate this further.Video Abstract available for this article.Trial RegistrationNCT00960440, NCT00847613, NCT00814307, NCT00856544, NCT00853385, NCT02187055.Video Abstract (MP4 204475 KB) (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - November 5, 2023 Category: Rheumatology Source Type: research
Serum Calprotectin as a Potential Predictor of Microvascular Manifestations in Patients with Antiphospholipid Syndrome
ConclusionSerum calprotectin levels are increased in aPL-positive patients and could be a potential predictor of microvascular manifestations. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - October 31, 2023 Category: Rheumatology Source Type: research
Clinical Outcomes in Patients with Rheumatoid Arthritis After Switching Between Interleukin-6-Receptor Inhibitors and Janus Kinase Inhibitors: Findings from an Observational Study
ConclusionsPatients with RA can achieve improvement in response when switching between IL-6Ri and JAKi. Although both therapies affect the IL-6 pathway, there are distinct mechanisms of action, which likely contribute to their clinical improvement, when reciprocally switched as follow-on treatments. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - October 31, 2023 Category: Rheumatology Source Type: research
Safety, Tolerability, and Pharmacokinetics of Same-Knee Intra-Articular Injection of Corticosteroid and Lorecivivint Within 7 Days: An Open-Label, Randomized, Parallel-Arm Study
ConclusionNo safety signals were observed. There were no quantifiable plasma concentrations of LOR in either Treatment Sequence. The PK of TCA was unaffected by previous LOR injection. These results suggest that IA administration of LOR and TCA in close time proximity is unlikely to pose a safety concern.Trial RegistrationClinicalTrials.gov identifier, NCT04598542. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - October 30, 2023 Category: Rheumatology Source Type: research
Pregnancy Outcomes in Patients with Primary Sj ögren’s Syndrome Undergoing Assisted Reproductive Therapy: A Multi-center Retrospective Study
ConclusionsART is an effective method for infertility in patients with pSS. Premature delivery is the leading maternal APOs. The incidence of fetal APOs does not increase, while birthweight is lower in offspring from pSS mothers with ART. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - October 24, 2023 Category: Rheumatology Source Type: research
A Model to Predict Future Biologic or Targeted Synthetic DMARD Switch at a Subsequent Clinic Visit in Rheumatoid Arthritis
ConclusionWe have developed a simple model to determine the probability of switching biologics for RA at the following clinic visit. This model could be used in practice to provide clinicians with more information about their patient ’s trajectory and likelihood of switching to a new biologic. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - October 19, 2023 Category: Rheumatology Source Type: research
Ixekizumab Efficacy in Patients with Severe Peripheral Psoriatic Arthritis: A Post Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (SPIRIT-P1)
ConclusionsIn patients with severe psoriatic arthritis, 24 weeks of treatment with ixekizumab resulted in improvements in both joint and skin symptoms. The safety profile in the severe population was consistent with the established safety profile of ixekizumab.Trial RegistrationClinicalTrials.gov identifier, NCT01695239. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - October 19, 2023 Category: Rheumatology Source Type: research
